Clinical, Biochemical, Radiological, and Genetic Analyses of a Patient with VCP Gene Variant-Induced Paget’s Disease of Bone
- 20 November 2021
- journal article
- research article
- Published by Springer Nature in Calcified Tissue International
- Vol. 110 (4) , 518-528
Abstract
Paget’s disease of bone (PDB) is a rare metabolic bone disorder, which is extremely rare in Asian population. This study aimed to investigate the phenotypes and the pathogenic mutations of woman with early-onset PDB. The clinical features, bone mineral density, x-ray, radionuclide bone scan, and serum levels of alkaline phosphatase (ALP), procollagen type 1 N-terminal propeptide (P1NP), and β-carboxy-terminal cross-linked telopeptide of type 1 collagen (β-CTX) were measured in detail. The pathogenic mutations were identified by whole-exon sequencing and confirmed by Sanger sequencing. We also evaluated the effects of intravenous infusion of zoledronic acid on the bones of the patient and summarized the phenotypic characteristics of reported patients with mutation at position 155 of the valosin-containing protein (VCP). The patient only exhibited bone pain as the initial manifestation with vertebral compression fracture and extremely elevated ALP, P1NP, and β-CTX levels; she had no inclusion body myopathy and frontotemporal dementia. The missense mutation in exon 5 of the VCP gene (p.Arg155His) was identified by whole-exome sequencing and further confirmed by Sanger sequencing. No mutation in candidate genes of PDB, such as SQSTM1, CSF1, TM7SF4, OPTN, PFN1, and TNFRSF11A, were identified in the patient by Sanger sequencing. Rapid relief of bone pain and a marked decline in ALP, P1NP, and β-CTX levels were observed after zoledronic acid treatment. Previously reported patients with VCP missense mutation at position 155 (R155H) always had myopathy, frontotemporal dementia, and PDB, but the patient in this study exhibited only PDB. This was the first report of R155H mutation-induced early-onset in the VCP gene in Asian population. PDB was the only manifestation having a favorable response to zoledronic acid treatment. We broadened the genetic and clinical phenotype spectra of the VCP mutation.Keywords
Funding Information
- National Natural Science Foundation of China (No.81873668, 82070908)
- Beijing Natural Science Foundation (7202153)
- National Key R&D Program of China (2018YFA0800801)
This publication has 40 references indexed in Scilit:
- Psychiatric Presentation of Frontotemporal Dementia Associated with Inclusion Body Myopathy due to the VCP Mutation (R155H) in a French FamilyCase Reports in Neurology, 2013
- A novel VCP mutation as the cause of atypical IBMPFD in a Chinese familyBone, 2013
- Genome-wide association identifies three new susceptibility loci for Paget's disease of boneNature Genetics, 2011
- A novel ATP‐dependent conformation in p97 N–D1 fragment revealed by crystal structures of disease‐related mutantsThe EMBO Journal, 2010
- Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and boneHuman Molecular Genetics, 2010
- Hereditary Inclusion Body Myopathy-Linked p97/VCP Mutations in the NH2 Domain and the D1 Ring Modulate p97/VCP ATPase Activity and D2 Ring ConformationMolecular and Cellular Biology, 2009
- Valosin-containing protein disease: Inclusion body myopathy with Paget’s disease of the bone and fronto-temporal dementiaNeuromuscular Disorders, 2009
- NF-κB functions in osteoclastsBiochemical and Biophysical Research Communications, 2009
- Paget's Disease of Bone and Genetic Disorders of RANKL/OPG/RANK/NF‐κB SignalingAnnals of the New York Academy of Sciences, 2006
- Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing proteinNature Genetics, 2004